EUVIMEDEUVIMED entdecken
Crossref

The UW Experience: Feasibility of De Novo Letermovir for Primary Prophylaxis After Abdominal Solid Organ Transplant

Jillian L Descourouez iD, Hanna Kleiboeker, Christopher M Saddler, Jeannina A Smith, John P Rice, Didier A Mandelbrot, Jon S Odorico, Margaret R Jorgenson iD

Annals of Pharmacotherapy · 2025

DOI: 10.1177/10600280241307383 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Jillian L Descourouez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Wisconsin Hospital and Clinics, UW Health, Madison WI, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Antiviral Agents, Organ Transplantation, Acetates. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Letermovir is approved for primary prophylaxis of cytomegalovirus (CMV) in high-risk kidney transplant recipients. However, many experts suggest the drug be reserved as a second-line agent when valganciclovir is not tolerated or fails.

Objective

The purpose of this study was to describe the feasibility of a de novo letermovir prophylactic approach for CMV high-risk and seropositive abdominal solid organ transplant patients.

Methods

Retrospective review of abdominal transplant recipients who required CMV prophylaxis between June 6, 2023, and June 6, 2024. The purpose was to evaluate feasibility of universal letermovir prophylaxis and prophylaxis success.

Results

278 patients required CMV prophylaxis and 207 obtained letermovir (74% success). Mean time from transplant to drug approval was 10.5 ± 27 days. Mean out of pocket patient cost was $10.19 ± $36.06 per 28-day supply of letermovir and $55.69 ± $311.48 per 30-day supply of valganciclovir ( P = 0.0419). For patients who obtained letermovir, 107 (52%) required prior authorization; 32 (16%) required insurance appeal after denial of prior authorization. Forty-two patients (20%) used Merck copay assistance program while 23 (11%) used the Merck Access patient assistance program to obtain drug. There were no episodes of prophylaxis failure due to breakthrough replication necessitating termination. Conclusion and Relevance: De novo use of letermovir for CMV primary prophylaxis after abdominal transplant was found to be feasible with a high rate of success in obtaining the drug in a timely manner posttransplant and without significant out-of-pocket cost to the patient.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsAntiviral AgentsOrgan TransplantationAcetatesHumansMaleRetrospective StudiesFemaleMiddle AgedFeasibility StudiesAdultAgedPrimary PreventionQuinazolines

Stichwörter der Autor:innen

cytomegalovirusde novoletermovirprophylaxistransplant

Substanzen

letermovirAntiviral AgentsAcetatesQuinazolines

Autor:innen und Institutionen

  • Department of Pharmacy, University of Wisconsin Hospital and Clinics, UW Health, Madison WI, USA.
  • Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, WI, USA.
  • Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, University of Wisconsin Hospitals and Clinics, Madison, WI, USA.

ORCID-Profile: Jillian L Descourouez, Margaret R Jorgenson

Zitieren

APA

Descourouez, J. L., Kleiboeker, H., Saddler, C. M., Smith, J. A., Rice, J. P., Mandelbrot, D. A., Odorico, J. S., & Jorgenson, M. R. (2025). The UW Experience: Feasibility of De Novo Letermovir for Primary Prophylaxis After Abdominal Solid Organ Transplant. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241307383

Vancouver

Descourouez JL, Kleiboeker H, Saddler CM, Smith JA, Rice JP, Mandelbrot DA, et al. The UW Experience: Feasibility of De Novo Letermovir for Primary Prophylaxis After Abdominal Solid Organ Transplant. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280241307383

BibTeX
@article{Descourouez2025,
  author = {Descourouez, Jillian L and Kleiboeker, Hanna and Saddler, Christopher M and Smith, Jeannina A and Rice, John P and Mandelbrot, Didier A and Odorico, Jon S and Jorgenson, Margaret R},
  title = {The UW Experience: Feasibility of De Novo Letermovir for Primary Prophylaxis After Abdominal Solid Organ Transplant},
  journal = {Annals of Pharmacotherapy},
  year = {2025},
  doi = {10.1177/10600280241307383}
}
Kostenlos starten →